Retinal Diseases: Wet and Dry AMD, Diabetic Retinopathy Market 2016-2026: Aflibercept, Ranibizumab, Bevacizumab, Verteporfin, Ocriplasmin, Anti-VEGF, Anti-PDGF

Retinal Diseases: Wet and Dry AMD, Diabetic Retinopathy Market 2016-2026: Aflibercept, Ranibizumab, Bevacizumab, Verteporfin, Ocriplasmin, Anti-VEGF, Anti-PDGF

  • July 2016 •
  • 208 pages •
  • Report ID: 4181574
A new report by DART Markets forecasts the overall world market for treating age-related macular degeneration (AMD or ARMD), diabetic retinopathy (DR) and other disorders of the retina will reach $17.38bn in 2020. That revenue forecast and others appear in Retinal Diseases: Wet and Dry AMD, Diabetic Retinopathy Market 2016-2026: Aflibercept, Ranibizumab, Bevacizumab, Verteporfin, Ocriplasmin, Anti-VEGF, Anti-PDGF, published in July 2016.

This 208-page report provides quantitative and qualitative information on 10-years revenue forecasts to 2026 at overall world market, disease submarkets, product (brand) and national market level presented in 121 charts and discussion. The study gives revenue predictions to 2026 for four therapeutic submarkets at world level:

- Wet age-related macular degeneration (wAMD)

- Dry AMD (dAMD)

- Diabetic retinopathy (DR)

- Other retinal diseases (grouped forecast).



The study also provides revenues and forecast of five prominent drugs to 2026:

- Lucentis

- Eylea

- Avastin

- Visudyne

- Jetrea



This report discusses the competitive landscape in the retinal diseases drugs market, which includes discussion on SWOT, STEP, Leading Companies, and M&A activities in this market.

Research, data and analyses cover activities of leading companies in the retinal diseases drugs industry:
- Roche

- Novartis

- Bayer

- Regeneron

- Allergan

- Valeant

- Other manufacturers and marketers of ophthalmic pharmaceuticals



This new study also discusses leading pipeline candidates for Wet AMD, Dry AMD, and Diabetic Retinopathy, shows two interviews and predicts revenues to 2026 in 11 leading national markets.

The work analyses these national markets:

- US

- Japan

- EU5 (Italy, Spain, Germany, the UK and France)

- BRIC (Brazil, Russia, India and China)

- Rest of the World


This report also provides a separate chapter on Pricing, Reimbursement, Market Access and Regulations, providing insights on these national markets:

- US

- Japan

- EU5

- Emerging Markets
Industry=Pathology ParentIndustry=LifeSciences Date=201607 Topic=MarketShares Publisher=DARTMarkets Price=5000